SCHEMBL1127306

SCHEMBL1127306

Nc1ccc(NS(=O)(=O)C2CC2)cc1S(N)(=O)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 2/20 0.44
BRPF1 P55201 2/20 0.44
BRD4 O60885 4/20 0.41
HDAC4 P56524 1/20 0.40
KIT P10721 3/20 0.39
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CYP2C9 P11712 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
CYP17A1 P05093 1/20 0.38
MAP2K4 P45985 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392853 0.77 CA12 (0.55) BRPF1CA12CA1CA2CYP2C9
SCHEMBL3088517 0.74 SGK1 (0.51) SGK1BRPF1HDAC4KITCA1
SCHEMBL3088257 0.73 HTR6 (0.56) SGK1BRPF1HDAC4KITMAP2K4
SCHEMBL18112987 0.73 BRPF1 (0.45) SGK1BRPF1BRD4HDAC4KIT
SCHEMBL1127809 0.73 BRPF1 (0.43) BRPF1BRD4EPHX2NR1H4CA12
Hydrochloric Acid SCHEMBL18953642 0.73 SGK1 (0.50) SGK1BRPF1HDAC4KITCA1
Hydrochloric Acid SCHEMBL18953653 0.72 HTR6 (0.54) SGK1BRPF1HDAC4KITMAP2K4
SCHEMBL18757743 0.72 SGK1 (0.46) SGK1BRPF1BRD4HDAC4KIT
SCHEMBL3374738 0.70 MEN1 (0.51) SGK1BRPF1BRD4HDAC4EPHX2
SCHEMBL18112945 0.70 KIT (0.47) SGK1BRPF1BRD4HDAC4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102026990-A Novel inhibitors of hepatitis c virus replication INTERMUNE INC 2011-04-20 CN disclosed
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF SGK1 1672/4885BRPF1 2781/4885BRD4 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.